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dermatitis, optimal emollient use, and 
response (or lack thereof) to topical 
therapies remains to be seen. However, 
Brown et al. (2012) identify an impor-
tant therapeutic consideration, namely, 
that a 5–10% increase in FLG in the skin 
could be clinically useful. Current work 
to identify drugs, small molecules, and 
compounds with the capacity to upregu-
late FLG expression is therefore expected 
to be of considerable value in improv-
ing the management of atopic dermatitis 
and other skin and systemic disorders in 
which a primary or secondary reduction 
in FLG expression contributes to disease 
pathophysiology.
In pursuit of this therapeutic target, 
a number of compounds have already 
been shown to increase FLG expression 
in keratinocytes. For example, oleanolic 
acid and ursolic acid—pentacyclic tri-
terpenoids that occur naturally in many 
medicinal herbs and plants—have both 
been shown to improve skin barrier func-
tion by increasing FLG expression (Lin et 
al., 2007), and many more compounds 
with similar, or perhaps superior, FLG-
promoting properties are likely to be 
discovered soon. A therapeutic future 
that can be extrapolated from the report 
by Brown et al. (2012) is one in which 
increasing FLG expression in individuals 
with lower intragenic copy number FLG 
allele variants has the potential to improve 
skin barrier integrity and reduce disease 
burden for several disorders. There is a 
clear translational route to follow, one 
that is likely to have huge clinical impact 
in the not too distant future. Size, when 
it comes to FLG intragenic copy number 
variation, really does matter.
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Dermatology Life Quality Index: Time 
to Move forward
Tamar Nijsten1
Since its introduction in 1994, the Dermatology Life Questionnaire Index (DLQI) 
has played an important role in assessing dermatology-specific health-related 
quality of life (HRQoL) and has affected several medical decision-making pro-
cesses. However, the psychometric requirements for instruments have evolved 
over the years, and the DQLI is failing these new standards. Therefore, it is time 
to move forward and use valuable alternatives because the DLQI’s scientific lim-
itations outweigh the practicalities of its use.
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The Dermatology Life Questionnaire 
Index (DLQI) (Finlay and Kahn, 
1994), the first dermatology-specific 
health-related quality-of-life (HRQoL) 
instrument, has helped enormously 
to introduce and assess HRQoL in 
dermatology. Studies have shown that 
the DLQI captures specific informa-
tion that is missed by generic HRQoL 
instruments such as the SF-36, illustrat-
ing the need for dermatology-specific 
questionnaires. Although the DLQI was 
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without input from patients. Several 
(classic test) psychometric properties 
were considered at the time of con-
ception (e.g., validity and reliability), 
but others were evaluated only after 
its introduction (e.g., responsiveness, 
dimensionality, and item functioning). 
These instruments were not likely to 
be adjusted afterward. The second gen-
eration of instruments was developed 
using the psychometric knowledge 
available at the time. From a pool of 
items created in collaboration with psy-
chologists and patients, statistical tests 
were used to select the items for the 
(pre)final instrument. Subsequent test-
ing of the HRQoL instrument changed 
the (total number of) instruments’ 
items. The Skindex-29 is the best 
example of second-generation HRQoL 
instruments. In the past decade, the use 
of item response theory (IRT) models 
has expanded and is now considered 
the gold standard (McHorney, 1997; 
Tennant et al., 2004). In addition to 
the trinity of psychometric properties 
(validity, reliability, and responsive-
ness), third-generation instruments 
have been created using modeling that 
provides detailed information about 
dimensionality, response categories, 
and differential item functioning.
None of the existing dermatology-
specific HRQoL instruments can be 
considered a true third-generation tool, 
but several disease-specific question-
naires have been developed using IRT 
models (Whalley et al., 2004). Several 
attempts have been made to upgrade 
existing instruments. A more in-depth 
analysis of the properties of the DLQI 
does not make it a second-genera-
tion instrument if it is not adjusted 
accordingly. Likewise, applying Rasch 
analysis, a one-parameter IRT model, 
to first- and second-generation instru-
ments does not make these instruments 
third generation. Applying the Rasch 
model to the Skindex-29 demonstrated 
that the 29 items did not fit the model, 
but after the developers deleted 12 
items, creating two scales instead of 
three, and regrouping the response cat-
egories, the Skindex did fit the model 
and has been renamed the Skindex-17 
(Nijsten et al., 2007). The current 
study by Twiss et al. (2012) confirms 
preliminary findings of previous studies 
designed for clinical dermatology prac-
tice (Finlay and Khan, 1994), it is now 
used to reflect patients’ perspectives 
in important medical decision-making 
processes, such as treatment indica-
tions, reimbursement criteria, and 
treatment goals, and as an important 
outcome measure in observational and 
interventional research. If the stakes 
are this high, it could even be argued 
that disease-specific instruments may 
provide more precise and valuable 
information than dermatology-specific 
instruments (e.g., a psoriasis-specific 
HRQoL questionnaire may be better in 
selecting patients eligible for and moni-
toring the effects of a biological therapy 
than less specific dermatology tools).
The DLQI’s ubiquity and impres-
sive track record convey several advan-
tages. Dermatologists are familiar 
with the DLQI; it has been accepted 
as the standard to measure HRQoL for 
dermatology patients by physicians, 
researchers, and regulatory agencies; 
it is available in many languages; and 
it may serve as a historical compara-
tor. Moreover, it is reliable, valid, and 
easy to use. Nonetheless, these practi-
cal benefits (and people’s reluctance to 
change) should not outweigh impor-
tant theoretical limitations (De Korte et 
al., 2002; Nijsten et al., 2006a; Both et 
al., 2007; Twiss et al., 2012, this issue), 
especially when the continued use of 
this instrument may have far-reaching 
clinical and financial consequences. 
The DLQI’s questions focus on physical 
limitations, and few items address the 
frequent psychological impact of skin 
diseases, suggesting a low conceptual 
validity (Muldoon et al., 1998). In prac-
tice, this implies that the DLQI is better 
at assessing the impact of severe (inflam-
matory) diseases than that of diseases 
with a relatively mild impact or with 
few physical symptoms but high psy-
chological impact (such as vitiligo, alo-
pecia areata, and basal cell carcinoma). 
Initially, the 10 questions were grouped 
into five scales without any formal sta-
tistical testing such as factor analysis, 
and a total score was advocated (Finlay 
and Khan, 1994). This is a contradiction 
of terms: scales require separate scale 
scores and obviate an overall score. On 
the other hand, calculating a total score 
implies that the questions all address the 
same underlying construct (i.e., a uni-
dimensional instrument) and that there 
are no scales. Formal factor analysis 
and Rasch analysis could not confirm 
the proposed (uni)dimensionality of the 
DLQI (McKenna et al., 2004; Nijsten et 
al., 2006a).
The DLQI suffers from item bias 
(i.e., significant “differential item func-
tioning”): the item responses of more 
than half of the questions are affected 
by external factors such as age, gen-
der, diagnosis (as demonstrated in this 
issue by Twiss et al.), and national-
ity (Nijsten et al., 2006b, 2007), not 
solely by the level of HRQoL impair-
ment. Theoretically, this implies that 
responses to the DLQI by old men and 
young women with a similar HRQoL 
impairment cannot be compared, that 
the scores for patients with psoria-
sis cannot be directly compared with 
those of patients with atopic derma-
titis, and that Italian patients respond 
differently to some of the items than 
do Dutch patients. Although this may 
seem a theoretical concern at first, it 
becomes a real problem if the DLQI is 
used to assess the impact of a disease in 
heterogeneous patient populations, to 
compare HRQoL impairment between 
diseases, or as an outcome measure 
in large international clinical trials. In 
other studies, the Skindex-17 showed 
much less item bias for these factors, 
confirming the feasibility of achieving 
these desirable measurement proper-
ties (Nijsten et al., 2006b, 2007).
Looking back at the past 20 years 
since the introduction of the DLQI, I 
see three generations of HRQoL instru-
ments in dermatology. The DLQI is an 
example of first-generation instruments 
that were developed on an intuitive 
basis in the early days of dermato-
logic psychometric research. Items 
were often created and selected by the 
researchers based on existing tools, 
|Instruments that  assess quality of life have evolved and 
continue to evolve.
commentary
 www.jidonline.org 13
demonstrating that the DLQI has sev-
eral intrinsic limitations that cannot 
be solved by adjusting this instrument. 
Interestingly, the Cardiff research group 
that developed the DLQI is now using 
Rasch analysis in the creation of new 
HRQoL questionnaires (Basra et al., 
2011), confirming the acceptance of 
this theoretical framework as the way 
forward in (dermatologic) HRQoL and 
patient-reported-outcome research.
For now, the Skindex-29 (or -17) 
is the preferred dermatology-specific 
instrument, but it is time to raise the bar 
for HRQoL and other patient-reported-
outcome instruments used to assess 
patients’ experiences. The fast-growing 
importance of these measures in medi-
cine is a big step forward, but their 
growing importance obliges us to create 
and use the best available instruments. 
This responsibility requires dedicated 
experts performing methodological 
HRQoL research and a community will-
ing to reach higher than before.
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Targeting Skin: Vitiligo  
and Autoimmunity
Anne M. Bowcock1,2 and Marcelo Fernandez-Vina3
In this issue, Singh and co-workers describe the results of classical typing of 
human leukocyte antigen (HLA) alleles in 1,404 vitiligo patients and 902 unaf-
fected controls from North India and follow-up HLA typing in 355 cases and 
441 controls from Gujarat. The increased frequency of DRB1*07:01 in North 
Indian and Gujarat populations with generalized and localized vitiligo and in 
several vitiligo populations studied previously suggests that it contributes to 
autoimmunity and destruction of melanocytes.
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of autoimmune diseases, including 
thyroid disease (particularly hypothy-
roidism), pernicious anemia, Addison’s 
disease, and systemic lupus erythema-
tosus, and there is an increased risk of 
these diseases and of vitiligo itself in 
close relatives (Alkhateeb et al., 2003). 
Its exact cause is unknown, but it is 
thought to result from a combination of 
environmental and genetic risk factors. 
Prevailing theories of the pathogenesis 
of vitiligo have ranged from its being a 
free radical disorder to an autoimmune 
disease (Schallreuter et al., 2008). 
Vitiligo first presents as hypomelanotic 
macules that are typically first noticed 
on sun-exposed areas of skin, such as 
the face and dorsal hands (Figure 1) 
(Ortonne, 2008).
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Vitiligo is a disfiguring pigmentary disor-
der that is attributable to the destruction 
of melanocytes from the skin, hair, and 
mucous membranes (Kemp et al., 2001; 
Spritz, 2008) (Figure 1). It is an ancient 
disease whose name was coined by 
the Roman physician Celsus in the sec-
ond century ad (Prasad and Bhatnagar, 
2003), who drew an analogy with its 
characteristic white patches to those of 
a spotted calf (“vitelius”). The disease 
affects 1 to 4% of the world’s popula-
tion (Ortonne and Bose, 1993), includ-
ing 1–2 million people in the United 
States, and it has a significant impact on 
quality of life because of its psychoso-
cial effects. Most individuals develop 
the disease by their third decade of life. 
It can go hand in hand with a multitude 
